Pharmacy, Hôpital Bichat-Claude Bernard, APHP, 46 rue Henri Huchard, 75877 Paris Cedex 18, France.
Lung Cancer. 2011 Apr;72(1):114-8. doi: 10.1016/j.lungcan.2010.07.004. Epub 2010 Aug 10.
Chemotherapy-induced alopecia may have a substantial impact on the quality of life (QOL) of lung cancer patients, but very few data are available. The aim of this study was to assess the perceived impact of alopecia based on a "willingness to pay" (WTP) approach.
We conducted a prospective multicenter WTP study of patients receiving chemotherapy for non-small-cell lung cancer (NSCLC). The perceived impact of alopecia was assessed with a visual analogue scale (VAS; 0: no impact, 10: major impact), and from the patients' willingness to pay for chemotherapy that had the same efficacy, dosing schedule and tolerability as the standard treatment but that cut the risk of alopecia from 40% to 5%.
Among the 135 patients enrolled in this study, the mean score on the VAS for the perceived likely impact of alopecia was 4.4 ± 0.3. The mean WTP for a 3-week chemotherapy cycle reducing the risk of alopecia from 40% to 5% was €83.4 ± 10.2 (€median 37.5), representing 2.1% of total income, while 27% of patients were unwilling to pay anything. There was a significant association between WTP and gender (women, p < 0.01), annual incomes (p < 0.01), but not with marital status, level of education or occupations.
Alopecia appears to be an important outcome for patients receiving chemotherapy for NSCLC. Women and patients with high annual incomes were more willing to pay.
化疗引起的脱发可能对肺癌患者的生活质量（QOL）产生重大影响，但目前可用的数据很少。本研究旨在通过“意愿支付”（WTP）方法评估脱发的感知影响。
我们对接受非小细胞肺癌（NSCLC）化疗的患者进行了前瞻性多中心 WTP 研究。脱发的感知影响通过视觉模拟量表（VAS；0：无影响，10：重大影响）进行评估，并根据患者对疗效相同、剂量方案和耐受性与标准治疗相同但将脱发风险从 40%降低到 5%的化疗的意愿支付。
在这项研究中纳入的 135 名患者中，VAS 评估的脱发感知可能影响的平均得分为 4.4±0.3。为了降低 3 周化疗周期中脱发风险从 40%到 5%的风险，每个周期的平均 WTP 为 83.4±10.2 欧元（中位数 37.5 欧元），占总收入的 2.1%，而 27%的患者不愿意支付任何费用。WTP 与性别（女性，p<0.01）、年收入（p<0.01）显著相关，但与婚姻状况、教育程度或职业无关。
脱发似乎是接受 NSCLC 化疗的患者的一个重要结果。女性和高年收入的患者更愿意支付。
